Clearside Biomedical (NSDQ:CLSD) said yesterday that Regenxbio (NSDQ:RGNX) exercised its option to license Clearside’s in-office SCS Microinjector for delivering adeno-associated virus (AAV)-based therapeutics in treating wet age-related macular degeneration, diabetic retinopathy and other conditions.
The two companies inked the option and licensing deal that they said at the time could be worth more than $130 million on Sept. 5. Under the agreement, Clearside earned $2 million after Regenxbio pulled the trigger on the option.
Get the full story at our sister site, Drug Delivery Business News.
